Chong Kun Dang Pharmaceutical: Changes of 30% or more in sales or profit/loss (15% or more in the case of large companies)







Disclosure review report
1. Information documents in connection with the review 30% or more change in sales or profit/loss (15% or more for larger companies)
2. Date of submission of documents 2022-02-10
3. Reason for revision Correction due to changes in the financial statements since the last disclosure date (2022-02-10)
4. Revised Information
information before revision after revision
2. Details of changes (in thousands of KRW)

Operating result
– Current fiscal year
– Amount increased/decreased
– Rate of increase/decrease (%)

Net income from continuing operations before income tax
– Current fiscal year
– Amount increased/decreased
– Rate of increase/decrease (%)

Net revenue
– Current fiscal year
– Amount increased/decreased
– Rate of increase/decrease (%)

96,686,594
-27,249,285
-22.0

82,521,754
-39 317 203
-32.3

43,817,821
-46,587,068
-51.5

94,758,694
-29 177 185
-23.5

80 593 854
-41 245 103
-33.9

42,356,472
-48 048 417
-53.1

3. Financial situation (in thousands of KRW)
– Total assets
– Total responsibilities
– Total equity
– Total equity/share capital ratio (%)
1,046,233,520
478 962 529
567 270 992
1,985.9
1,046,700,072
480 890 429
565 809 643
1,980.8
[Matters Related to the Controlling Company]
– Total equity (excluding equity of minority shareholders)
– Total equity/share capital ratio (%) (excluding non-controlling equity)
567 471 333

1,986.6

566 009 985

1981.5

– The above financial statements have not been audited by an external auditor and are subject to change depending on the results of the audit.

Changes of 30% or more in sales or profit/loss (15% or more in the case of large companies)

※ Note that this disclosure is indicated by the relevant company, so the details may be changed depending on the results of the audit. Refer to the “Audit Report Submission” disclosure for finalized details.
1. Type of financial statements Consolidated financial statements
2. Details of changes (in thousands of KRW) Current year Previous exercice Amount increased/decreased Rate of increase/decrease (%)
– Sales (limited to the amount of revenue based on sales of goods and services provided) 1,343,559,363 1,303,005,524 40,553,839 3.1
– Operating result 94,758,694 123 935 879 -29 177 185 -23.5
– Net income from continuing operations before income tax 80 593 854 121 838 957 -41 245 103 -33.9
– Net revenue 42,356,472 90 404 889 -48 048 417 -53.1
– Classified as a large company? No
3. Financial situation (in thousands of KRW) Current year Previous exercice
– Total assets 1,046,700,072 946 333 120
– Total responsibilities 480 890 429 394 740 342
– Total equity 565 809 643 551 592 778
– share capital 28,565,248 27 214 213
– Total equity/share capital ratio (%) 1,980.8 2,026.9
4. Main causes of variations in sales or amount of profit/loss Reduction in net income due to non-recurring costs and increase in R&D costs.
5. Council resolution date (decision date) 2022-02-10
– Presence of external directors Present (No.) 2
Absent (Nb) 0
– Presence of the statutory auditors (members of the Audit Committee who are not outside directors) Gift
6. Other things to consider in investment decisions
– The current year documents above are based on consolidated financial statements prepared in accordance with Korean International Financial Reporting Standards (K-IFRS).

– The above data has not been audited by an external auditor and as such is subject to change in the future.

※ Related Disclosure
[Matters Related to Parent Company]
Category financial state Current year Previous exercice
Total equity (excluding equity of non-controlling shareholders) Consolidated financial statements 566 009 985 551 426 758
Total equity/share capital ratio (%) (excluding non-controlling equity) Consolidated financial statements 1,981.5 2,026.2
Amount of sales (limited to amount of revenue based on sales of goods and services provided) (in thousands of KRW) Non-consolidated financial statements 1,333,988,910 1,300,544,358

Warning

Chong Kun Dang Pharmaceutical Company published this content on March 10, 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unmodified, on March 10, 2022 08:32:01 UTC.

Public now 2022

All news from CHONG KUN DANG PHARMACEUTICAL CORP.

Sales 2021 1,337B
1.09B
1.09B
Net income 2021 53.4B
0.04B
0.04B
Net cash 2021 40.3B
0.03B
0.03B
PER 2021 ratio 21.4x
2021 performance 0.96%
Capitalization 1,141B
931M
931M
EV / Sales 2021 0.82x
EV / Sales 2022 0.72x
# of employees 2,392
Floating 55.5%

Chart CHONG KUN DANG PHARMACEUTICAL CORP.


Duration :

Period :




Technical analysis chart of Chong Kun Dang Pharmaceutical Corp.  |  MarketScreener

Trends Technical Analysis CHONG KUN DANG PHARMACEUTICAL CORP.

Short term Middle term Long term
Tendencies Bullish Bearish Bearish



Evolution of the income statement

Medium consensus
Number of analysts 0
Last closing price

96,600.00

Average target price
Average Spread / Target


Comments are closed.